Microsoft: Q3 Earnings Consensus Estimates

Microsoft (NASDAQ: MSFT) will be reporting their fiscal third quarter financials on April 27th after market close. Analysts have a consensus $276.31 12-month price target on the company, via a total of 38 analysts, with 17 analysts having strong buy ratings. 17 analysts meanwhile have buy ratings and four have hold ratings. The street high comes from PNP Paribas with a $330 price target, and the lowest target sits at $180.

25 analysts have revenue estimates for the third quarter. The mean revenue estimate between all 25 analysts is $41 billion; this number has been revised upwards from $38.7 billion at the start of the year. The highest revenue estimate is $42 billion, while the lowest is $40.5 billion.

Onto EBITDA estimates, there are currently only 5 analysts who have third-quarter EBITDA estimates. The mean is currently $19 billion, with this number having been revised down from $17.4 billion at the start of the year. Street high is $19.5 billion EBITDA estimate and the lowest is $18.3 billion.

Analysts estimate that quarterly earnings per share will come in at $1.82, with this number being revised upwards from $1.58 at the start of the year. Street high is $1.93 and the lowest estimate is $1.69 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Copper Is Heading To $30 And Silver To $200 | Craig Parry

Mako Mining Q3 Earnings: The Transitional Quarter

B2Gold Q3 Earnings: Goose Troubles Cloud The Narrative

Recommended

Altamira Gold Appoints Dr Richard Sillitoe, Porphyry Expert, As Technical Advisor

Goliath Resources Extends Bonanza Zone To 1.25 Kilometres Length In Latest Assays

Related News

Mind Medicine: Canaccord Genuity Initiates Coverage With C$1.75 Price Target

Yesterday, Canaccord initiated coverage on Mind Medicine (NEO: MMED) with a Speculative Buy rating and...

Wednesday, September 16, 2020, 04:15:00 PM

Cronos Group: Analysts Expect Another Quarterly Loss For Q2

Cronos Group (TSX: CRON) announced that they will be reporting their second quarter financials before...

Wednesday, August 4, 2021, 03:50:00 PM

Xebec: Canaccord Views Three Year Plan As Ambitious, Without Risk

After an uneventful and lackluster quarter, Xebec Adsorption (TSX: XBC) provided investors with a three-year...

Friday, April 1, 2022, 03:43:00 PM

Plant 13: Canaccord Lowers Estimates Due To COVID Headwinds

On August 26, Planet 13 Holdings (CSE: PLTH) announced its second quarter financial results. The...

Monday, August 30, 2021, 04:49:00 PM

Sundial Growers: Analysts Expect Positive EBITDA For Second Quarter

Sundial Growers Inc. (Nasdaq: SNDL) announced that they will be reporting their second quarter financials...

Wednesday, August 11, 2021, 11:58:00 AM